Tatjana Gruber-Rouh, Presenter: Nothing to Disclose

Nagy Naguib Naeem Naguib MD, MSc, Abstract Co-Author: Nothing to Disclose

Nour-Eldin Abdelrehim Nour-Eldin MD, MSc, Abstract Co-Author: Nothing to Disclose

Martin Beeres MD, Abstract Co-Author: Nothing to Disclose

Julian Lukas Wichmann MD, Abstract Co-Author: Nothing to Disclose

Stefan Zangos MD, Abstract Co-Author: Nothing to Disclose

Thomas Josef Vogl MD, PhD, Abstract Co-Author: Nothing to Disclose

To evaluate local tumor control and survival data after TACE with three different chemotherapeutic protocols in the palliative treatment of patients with liver metastases from lung cancer

The study protocol was approved by the ethical committee, and informed consent was obtained from all patients prior to treatment. A total of 44 patients (mean age, 55.2 years; range, 42-78 years) with unresectable liver metastases of lung cancer who did not respond to systemic therapy were repeatedly treated with TACE in 4-week intervals. In total, 176 chemoembolization procedures were performed (mean, 4 sessions per patient; range, 3-6 sessions). The local chemotherapy protocol consisted of mitomycin alone (22.7%; n=10), mitomycin with gemcitabine (22.7%; n=10) or mitomycin, gemcitabine and cisplatin (54.6%, n=24). Embolization was performed with lipiodol and degradable starch microspheres. Local tumor response was evaluated by MRI according to the RECIST criteria. Survival data were calculated according to the Kaplan-Meier method.  

The local tumor control was: partial response (PR) in 15.9% (n=7), stable disease (SD) in 56.8% (n=25) and progressive disease (PD) in 27.3% (n=12) of patients. The 1-year survival rate after chemoembolization was 70%, and the 2-year survival rate was 38%. The median and mean survival times from the start of TACE treatment were 20 and 31.8 months. There was no statistically significant difference between the three treatment protocols.

Chemoembolization is a potentially palliative treatment option in achieving local control in selected patients with liver metastases from lung cancer.

Chemoembolization is a potentially palliative treatment option in achieving local control in selected patients with liver metastases from lung cancer.

Gruber-Rouh, T, Naguib, N, Nour-Eldin, N, Beeres, M, Wichmann, J, Zangos, S, Vogl, T, Transarterial Chemoembolization (TACE) as a Palliative Treatments Option for Liver Metastases from Lung Cancer: Indications, Outcomes and Role in Patient’s Management.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14045521.html